Esophagus News

WASHINGTON — In a Healio video exclusive, Carolyn Newberry, MD, discusses the importance of “personalized” lifestyle modifications, such as identifying dietary triggers and being mindful of meal-timing, for the management of GERD.

WASHINGTON — Among adults with eosinophilic esophagitis, weight gain while undergoing dietary therapy was associated with poor treatment response, regardless of baseline weight status, according to data presented at Digestive Disease Week.

WASHINGTON — Once-daily etrasimod 1 mg and 2 mg was well-tolerated and sustained improvements in histological and endoscopic features of eosinophilic esophagitis, as well as patient symptoms, through 52 weeks of treatment, according to data.

WASHINGTON — Vonoprazan effectively relieved heartburn symptoms in patients with nonerosive reflux disease as early as day 1 of treatment, with results persisting after a 4-week placebo-controlled period through 20 weeks, according to data.

WASHINGTON — Swallowed corticosteroid treatment did not impact growth velocity among children with eosinophilic esophagitis, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

In this Healio video, David A. Johnson, MD, MACG, FASGE, MACP, reminds physicians to ask patients with nocturnal heartburn or GERD about associated sleep disturbances, which can negatively affect “next-day functioning” and quality of life.

More than 300 million people worldwide, including one in every 10 Americans, are living with a rare disease, yet these individuals and their families are often left isolated and without answers.

The FDA has approved Takeda Pharmaceuticals’ Eohilia as the “first and only oral therapy” for treatment of eosinophilic esophagitis in patients aged 11 years or older, according to a press release.

The FDA granted 510(k) clearance to Cyted’s EndoSign, a non-endoscopic capsule sponge device intended to gather pan-esophageal samples for early detection of esophageal cancer as well as other conditions, according to a company release.

The FDA has granted an orphan drug designation to ’1104 from Revolo Biotherapeutics, a first-in-class immune-resetting peptide designed to treat eosinophilic esophagitis, according to a press release.